A Vaccine against Streptococcus pyogenes

@article{Guilherme2013AVA,
  title={A Vaccine against Streptococcus pyogenes},
  author={Luiza Guilherme and Frederico Moraes Ferreira and Karen Francine K{\"o}hler and Edilberto Post{\'o}l and Jorge Kalil},
  journal={American Journal of Cardiovascular Drugs},
  year={2013},
  volume={13},
  pages={1-4}
}
Streptococcus pyogenes causes severe, invasive infections such as the sequelae associated with acute rheumatic fever, rheumatic heart disease, acute glomerulonephritis, uncomplicated pharyngitis, and pyoderma. Efforts to produce a vaccine against S. pyogenes began several decades ago, and different models have been proposed. We have developed a vaccine candidate peptide, StreptInCor, comprising 55 amino acid residues of the C-terminal portion of the M protein and encompassing both the T- and B… Expand
Group A Streptococcus Vaccines
TLDR
Although RHD and severe invasive infections are the most fatal GAS syndromes, they are too uncommon and/or have too-long a latency period to be primary endpoints in clinical trials before licensure, and the status of GAS vaccine research and development is summarized. Expand
Novel platform technology for modular mucosal vaccine that protects against streptococcus
TLDR
An innovative vaccine strategy to induce mucosal antibodies of significant magnitude against peptide antigens of GAS using a novel biocompatible liposomal platform technology is described. Expand
Acute Rheumatic Fever: Global Persistence of a Preventable Disease.
  • Francine Bono-Neri
  • Medicine
  • Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners
  • 2017
TLDR
The persistence of acute rheumatic fever continues to be seen globally and prevention is the key to resolving the dilemma of the disease's global burden, yet the method to yield its prevention still remains unknown. Expand
Streptococcal acute pharyngitis.
TLDR
Future perspectives to prevent streptococcal pharyngitis and post-infection systemic complications include the development of an anti-Streptococcus pyogenes vaccine. Expand
Chapter 21 - Rheumatic Fever
TLDR
Rheumatic fever and rheumatic heart disease remain important causes of morbidity and mortality mainly in developing countries and the adequate treatment of streptococcal infections should be a target for political effort in order to prevent this devastating disease. Expand
The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics
TLDR
The role, status, and directions in GAS vaccines research are discussed, and demonstration of vaccine efficacy against pharyngitis and skin infections constitutes a key near-term strategic goal. Expand
Molecular epidemiology of group A streptococcus from pharyngeal isolates in Auckland, New Zealand, 2013.
TLDR
This study provides baseline data on the circulating pharyngeal GAS emm types in Auckland and provides future clinical and molecular surveillance of GAS pharyngitis is essential in the context of ongoing GAS vaccine development. Expand
Risk Factors Associated With Severe Acute Respiratory Infections Cases
TLDR
This study promotes positive social change by informing efforts to increase vaccination and health literacy, improve the accessibility and availability of preventive health care in low socioeconomic communities, and promote healthy lifestyles among at-risk groups. Expand
Mucosal immune responses to microbiota in the development of autoimmune disease.
TLDR
Current and emerging data suggest that dysregulated immune interactions with commensal microbiota may play a role in the initial generation of autoimmunity in this preclinical period. Expand
[Streptococcus pyogenes/group a streptococcus: an extra-cellular bacteria whose only known reservoir is man].
TLDR
This thesis aims to demonstrate the efforts towards in-situ applicability of EMMARM, which have been made in recent years in the area of pédiatrie and its applications in the context of hospitalier intercommunal medicine. Expand
...
1
2
...

References

SHOWING 1-10 OF 15 REFERENCES
A vaccine against S. pyogenes: design and experimental immune response.
TLDR
The methodology used in the development of a new vaccine model, consisting of both T and B protective epitopes constructed as synthetic peptides and recombinant proteins, is described, suggesting that the vaccine epitope is safe. Expand
Anti-Group A Streptococcal Vaccine Epitope
TLDR
StreptInCor-overlapping peptides induced cellular and humoral immune responses of individuals bearing different HLA class II molecules and could be considered as a universal vaccine epitope. Expand
Towards a Vaccine Against Rheumatic Fever
TLDR
Results strongly indicated that the selected T and B cell epitopes could potentially be protective against S. pyogenes in RF/RHD. Expand
Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.
  • S. Mcneil, S. Halperin, +11 authors J. Dale
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2005
TLDR
On the basis of epidemiological data demonstrating that the majority of cases of pharyngitis, necrotizing fasciitis, and other invasive streptococcal infections are caused by a limited number of serotypes, this 26-valent vaccine could have significant impact on the overall burden of streptitiscal disease. Expand
HLA class II transgenic mice develop a safe and long lasting immune response against StreptInCor, an anti-group A streptococcus vaccine candidate.
TLDR
The results showed that StreptInCor is able to induce robust and safe and long lasting immune response without deleterious reactions in several organs, indicating that it could be considered a safe vaccine against severe streptococcus-induced diseases. Expand
Preclinical evaluation of a vaccine based on conserved region of M protein that prevents group A streptococcal infection.
TLDR
The data obtained in the present study indicated that the chimeric peptide J8 from the conserved region of the M protein could form the basis for an anti-streptococcal vaccine in future. Expand
Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope.
TLDR
Data indicate that immunity to GAS infection can be evoked by intranasal immunisation with a GAS M protein C-region peptide vaccine that contains a protective B cell epitope and lacks a T cell autoepitope. Expand
Group A streptococcal vaccines: facts versus fantasy
TLDR
Several vaccine candidates against GAS infection are in varying stages of preclinical and clinical development, and only one, the multivalent N-terminal vaccine, has entered clinical trials in the last 30 years. Expand
Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial.
TLDR
These results provide the first evidence in humans that a hybrid fusion protein is a feasible strategy for evoking type-specific opsonic antibodies against multiple serotypes of group A streptococcus without eliciting antibodies that cross-react with host tissues, which represents a critical step in the development of a vaccine. Expand
Mapping T-cell epitopes in group A streptococcal type 5 M protein
TLDR
Helper T-cell epitopes located in the C-terminal region of M5 are likely to be widely conserved between different M serotypes and could be particularly useful in designing multivalent, defined-epitope M vaccines. Expand
...
1
2
...